Drug updated on 4/16/2024
| Dosage Form | Injection (45 mg, 60 mg lyophilized cake or powder in a single-dose vial) |
| Drug Class | Activin signaling inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Winrevair (sotatercept-dsrk) Prescribing Information | 2024 | Merck & Co., Rahway, New Jersey |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension | 2024 | American Journal of Cardiovascular Drugs |
| Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes | 2024 | Clinical Cardiology |